Melanocortin receptor research peptide for controlled laboratory studies.
- Dose
- 10 mg
- Batch
- 268010
MT-II (Melanotan II)
Acetyl-[Nle4, Asp5, D-Phe7, Lys10]-cyclo-α-MSH(4–10) amide (melanotan-II, MT-II)
For research purposes only — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Melanocortin receptor research peptide for controlled laboratory studies.
Members get 10% off every order, on top of volume pricing — become a member with a free account.
Volume savings are applied automatically at checkout. Larger orders: support@alptide.at
- Lab
- Janoshik Analytical
- Methods
- HPLC · LC-MS
For laboratory research use only. Not for human consumption.
Technical specifications
- Type
- Peptide
- Scientific name
- Acetyl-[Nle4, Asp5, D-Phe7, Lys10]-cyclo-α-MSH(4–10) amide (melanotan-II, MT-II)
- Amino acids
- 7
- Sequence
- Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
- Molecular weight
- 1024.2 g/mol
- Formula
- C50H69N15O9
- CAS
- 121062-08-6
- Origin
- Synthetic cyclic lactam heptapeptide analogue of α-MSH residues 4–10, designed at the University of Arizona (Al-Obeidi/Hruby, 1989); the Asp5–Lys10 lactam bridge forms a 23-membered ring.
- Lyophilized (powder)
- -20°C · stable long-term; keep sealed, desiccated and protected from light
- Reconstituted
- 2-8°C · use within 30 days; avoid repeated freeze-thaw cycles
- Room temperature
- Lyophilized powder tolerates short shipping excursions of a few days, but peptide in solution degrades within days at room temperature — reconstituted vials should not be held above 8°C.
Peer-reviewed research
Published research and registered trials involving this compound. Provided for educational reference only — none of it is a claim about this product.
- Journal of the American Chemical SocietyDesign of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulationsAl-Obeidi F, Hadley M, Pettitt B, Hruby V1989DOI: 10.1021/ja00191a044
- Journal of Medicinal ChemistryPotent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamicsAl-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ1989DOI: 10.1021/jm00132a010PMID: 2555512
- Life SciencesEvaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical studyDorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME1996DOI: 10.1016/0024-3205(96)00160-9PMID: 8637402
- NatureRole of melanocortinergic neurons in feeding and the agouti obesity syndromeFan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD1997DOI: 10.1038/385165a0PMID: 8990120
- The Journal of UrologySynthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover studyWessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N1998PMID: 9679884
- UrologyEffect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunctionWessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N2000DOI: 10.1016/s0090-4295(00)00680-4PMID: 11018622
- PeptidesMelanocortin peptide therapeutics: historical milestones, clinical studies and commercializationHadley ME, Dorr RT2006DOI: 10.1016/j.peptides.2005.01.029PMID: 16412534
- International Journal of DermatologyRisks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a reviewHabbema L, Halk AB, Neumann M, Bergman W2017DOI: 10.1111/ijd.13585PMID: 28266027
More in Melanocortin
PT-141
10 mg / vial
Melanocortin receptor research peptide for controlled laboratory studies.